Table 3.
Univariate analysis of characteristics associated with survival time
| Characteristics | DFS
|
OS
|
||
|---|---|---|---|---|
| 95% CI | P-value | 95% CI | P-value | |
| PN | 0.000 | 0.000 | ||
| Low | 36.956–51.836 | 48.360–59.017 | ||
| High | 13.966–23.566 | 24.236–34.147 | ||
| EGFR | 0.000 | 0.000 | ||
| Low | 37.550–55.485 | 47.035–61.181 | ||
| High | 16.351–24.649 | 27.441–36.152 | ||
| Gender | 0.373 | 0.331 | ||
| Male | 21.271–34.687 | 31.852–44.027 | ||
| Female | 24.945–40.166 | 35.867–49.036 | ||
| Age (years) | 0.584 | 0.546 | ||
| <60 | 19.137–37.152 | 29.366–45.160 | ||
| ≥60 | 24.655–36.853 | 35.689–46.615 | ||
| Tumor length (cm) | 0.264 | 0.220 | ||
| <5 | 25.480–37.151 | 35.969–46.099 | ||
| ≥5 | 15.396–31.804 | 25.374–43.426 | ||
| Tumor location | 0.649 | 0.619 | ||
| Upper/middle | 17.835–30.165 | 35.037–46.600 | ||
| Low | 15.569–26.431 | 30.543–42.877 | ||
| Invasion depth | 0.000 | 0.000 | ||
| pT1/pT2 | 36.041–54.311 | 44.896–59.614 | ||
| pT3 | 15.947–22.216 | 27.001–35.489 | ||
| Differentiation grade | 0.005 | 0.006 | ||
| Well/moderate | 26.948–38.574 | 37.663–47.527 | ||
| Poor | 11.006–22.137 | 18.018–35.982 | ||
| Venous invasion | 0.766 | 0.673 | ||
| Yes | 18.797–44.425 | 29.625–51.486 | ||
| No | 24.072–34.786 | 34.771–44.482 | ||
| Lymphatic metastasis | 0.000 | 0.000 | ||
| Yes | 14.575–22.787 | 25.498–34.459 | ||
| No | 35.893–51.616 | 45.828–58.365 | ||
| Stage | 0.000 | 0.000 | ||
| I/II | 35.340–49.321 | 45.546–56.700 | ||
| III | 11.563–16.381 | 21.328–29.295 | ||
Note: Bold P-values are statistically significant.
Abbreviations: DFS, disease-free survival; OS, overall survival; CI, confidence interval; PN, periostin; EGFR, epidermal growth factor receptor; pT, pathological T stage.